SHKNSES H Kelkar and Company Limited· Chemicals & PetrochemicalsHighNeutral
Announced Fri, 6 Feb, 2026 · 20:14 IST

S H Kelkar Q3 FY26: PAT turnaround, Re.1 interim dividend

Pat Growth 25pctExceptional ItemResults View source PDFExplain this filing

SHK · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+3.9%Reaction day
₹169.30
prior close
₹171.90
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+2.6%+1.3% vs market
Specialty Chemicals peers, median of 88sector+1.7%+2.2% vs sector

On the reaction day the stock moved 1.3 pts more than Nifty Microcap 250 and 2.2 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+4.5
10m
+4.7
15m
+4.6
30m
+1.9
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+3.9+2.6+1.3+1.7+2.2
Next day
+2.8+3.6-0.8+2.4+0.4
2d
+3.4+3.1+0.3+2.5+0.9
3d
+2.8+2.6+0.2+1.3+1.5
4d
-1.1+1.1-2.1+0.0-1.1
5d
-2.8+0.3-3.2-1.5-1.4
1w
-2.9+1.6-4.5-0.6-2.3
15d
-14.8-3.9-10.8-6.4-8.4
1m
-23.2-8.1-15.1-8.8-14.4
2m
-19.1-3.1-16.0-4.6-14.5
3m
-10.9+9.2-20.0+5.9-16.7
UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 88Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

S H Kelkar posted Q3 FY26 consolidated revenue of Rs.583.80 cr, up 7.5% YoY. Nine-month revenue rose 10.4 percent to Rs.1,718.32 cr. Nine-month PAT swung to a profit of Rs.67.35 cr from a loss of Rs.28.43 cr last year, aided by a Rs.62.17 cr exceptional gain from the Vashivali plant fire insurance claim. Q3 PAT rose to Rs.32.63 cr from Rs.17.51 cr. Board declared a Re.1 per share interim dividend (Rs.13.84 cr total). Also approved up to AED 5 million equity infusion into Keva Middle East FZE subsidiary. Deloitte Haskins and Sells gave an unmodified review.

Likely market impact

Strong PAT swing backed by insurance gain, steady revenue growth, and a small dividend. Likely positive for sentiment near term.